Do analysts prefer CYRX or OABI?

CryoPort presently has a consensus price target of $18.00, suggesting a potential upside of 19.05%. Given CryoPort's stronger consensus rating and higher possible upside, research analysts clearly believe CryoPort is more favorable than OmniAb. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CryoPort 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 OmniAb 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, CYRX or OABI?

CryoPort has higher revenue and earnings than OmniAb. CryoPort is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CryoPort $176.18M 4.35 $78.30M -$0.90 N/A OmniAb $38.46M 11.60 -$64.78M -$0.36 N/A

Is CYRX or OABI more profitable?

CryoPort has a net margin of -20.05% compared to OmniAb's net margin of -115.12%. CryoPort's return on equity of -7.20% beat OmniAb's return on equity. Company Net Margins Return on Equity Return on Assets CryoPort -20.05% -7.20% -4.30% OmniAb -115.12% -16.59% -14.82%

Does the media favor CYRX or OABI?

In the previous week, CryoPort had 8 more articles in the media than OmniAb. MarketBeat recorded 14 mentions for CryoPort and 6 mentions for OmniAb. OmniAb's average media sentiment score of 0.29 beat CryoPort's score of 0.27 indicating that OmniAb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral OmniAb 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend OABI or EVO?

Evotec has a consensus price target of $3.00, indicating a potential upside of 50.00%. Given Evotec's stronger consensus rating and higher probable upside, analysts clearly believe Evotec is more favorable than OmniAb. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OmniAb 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Evotec 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has better valuation & earnings, OABI or EVO?

OmniAb has higher earnings, but lower revenue than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OmniAb $38.46M 11.60 -$64.78M -$0.36 N/A Evotec $891.97M 0.80 -$117.12M N/A N/A

Is OABI or EVO more profitable?

Evotec has a net margin of -26.20% compared to OmniAb's net margin of -115.12%. OmniAb's return on equity of -16.59% beat Evotec's return on equity. Company Net Margins Return on Equity Return on Assets OmniAb -115.12% -16.59% -14.82% Evotec -26.20% -24.93% -11.35%

Does the media refer more to OABI or EVO?

In the previous week, Evotec had 1 more articles in the media than OmniAb. MarketBeat recorded 7 mentions for Evotec and 6 mentions for OmniAb. OmniAb's average media sentiment score of 0.29 beat Evotec's score of 0.02 indicating that OmniAb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OmniAb 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Evotec 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate MLAB or OABI?

Mesa Laboratories currently has a consensus price target of $94.00, indicating a potential downside of 8.43%. Given Mesa Laboratories' higher possible upside, equities analysts clearly believe Mesa Laboratories is more favorable than OmniAb. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesa Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 OmniAb 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, MLAB or OABI?

Mesa Laboratories has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesa Laboratories $249.13M 2.31 $6.71M $1.20 85.54 OmniAb $38.46M 11.60 -$64.78M -$0.36 N/A

Is MLAB or OABI more profitable?

Mesa Laboratories has a net margin of 2.69% compared to OmniAb's net margin of -115.12%. Mesa Laboratories' return on equity of 20.96% beat OmniAb's return on equity. Company Net Margins Return on Equity Return on Assets Mesa Laboratories 2.69% 20.96% 8.78% OmniAb -115.12% -16.59% -14.82%

Does the media favor MLAB or OABI?

In the previous week, OmniAb had 3 more articles in the media than Mesa Laboratories. MarketBeat recorded 6 mentions for OmniAb and 3 mentions for Mesa Laboratories. Mesa Laboratories' average media sentiment score of 0.67 beat OmniAb's score of 0.29 indicating that Mesa Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesa Laboratories 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OmniAb 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer DNA or OABI?

Ginkgo Bioworks presently has a consensus target price of $7.00, suggesting a potential downside of 12.01%. Given Ginkgo Bioworks' higher probable upside, equities analysts clearly believe Ginkgo Bioworks is more favorable than OmniAb. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ginkgo Bioworks 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33 OmniAb 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is DNA or OABI more profitable?

OmniAb has a net margin of -115.12% compared to Ginkgo Bioworks' net margin of -259.96%. OmniAb's return on equity of -16.59% beat Ginkgo Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks -259.96% -60.27% -26.88% OmniAb -115.12% -16.59% -14.82%

Does the media prefer DNA or OABI?

In the previous week, Ginkgo Bioworks had 5 more articles in the media than OmniAb. MarketBeat recorded 11 mentions for Ginkgo Bioworks and 6 mentions for OmniAb. Ginkgo Bioworks' average media sentiment score of 0.37 beat OmniAb's score of 0.29 indicating that Ginkgo Bioworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral OmniAb 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer OABI or CTKB?

Cytek Biosciences has a consensus target price of $5.56, suggesting a potential upside of 32.44%. Given Cytek Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cytek Biosciences is more favorable than OmniAb. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OmniAb 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cytek Biosciences 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is OABI or CTKB more profitable?

Cytek Biosciences has a net margin of -38.98% compared to OmniAb's net margin of -115.12%. Cytek Biosciences' return on equity of -12.40% beat OmniAb's return on equity. Company Net Margins Return on Equity Return on Assets OmniAb -115.12% -16.59% -14.82% Cytek Biosciences -38.98% -12.40% -9.17%

Does the media refer more to OABI or CTKB?

In the previous week, Cytek Biosciences had 2 more articles in the media than OmniAb. MarketBeat recorded 8 mentions for Cytek Biosciences and 6 mentions for OmniAb. Cytek Biosciences' average media sentiment score of 0.52 beat OmniAb's score of 0.29 indicating that Cytek Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OmniAb 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Cytek Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

OmniAb (OABI) Competitors

$3.08 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$3.16 +0.08 (+2.60%)

As of 09:17 AM Eastern

Compare

OABI vs. CYRX, EVO, MLAB, DNA, and CTKB

Should you buy OmniAb stock or one of its competitors? MarketBeat compares OmniAb with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OmniAb include CryoPort (CYRX), Evotec (EVO), Mesa Laboratories (MLAB), Ginkgo Bioworks (DNA), and Cytek Biosciences (CTKB). These companies are all part of the "life sciences tools & services" industry.

How does OmniAb compare to CryoPort?

CryoPort (NASDAQ:CYRX) and OmniAb (NASDAQ:OABI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

CryoPort has higher revenue and earnings than OmniAb. CryoPort is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.35	$78.30M	-$0.90	N/A
OmniAb	$38.46M	11.60	-$64.78M	-$0.36	N/A

CryoPort has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market. Comparatively, OmniAb has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

CryoPort presently has a consensus price target of $18.00, suggesting a potential upside of 19.05%. Given CryoPort's stronger consensus rating and higher possible upside, research analysts clearly believe CryoPort is more favorable than OmniAb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
OmniAb	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CryoPort has a net margin of -20.05% compared to OmniAb's net margin of -115.12%. CryoPort's return on equity of -7.20% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	-20.05%	-7.20%	-4.30%
OmniAb	-115.12%	-16.59%	-14.82%

In the previous week, CryoPort had 8 more articles in the media than OmniAb. MarketBeat recorded 14 mentions for CryoPort and 6 mentions for OmniAb. OmniAb's average media sentiment score of 0.29 beat CryoPort's score of 0.27 indicating that OmniAb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
OmniAb	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

92.9% of CryoPort shares are held by institutional investors. Comparatively, 72.1% of OmniAb shares are held by institutional investors. 9.5% of CryoPort shares are held by insiders. Comparatively, 9.8% of OmniAb shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

CryoPort beats OmniAb on 11 of the 16 factors compared between the two stocks.

How does OmniAb compare to Evotec?

OmniAb (NASDAQ:OABI) and Evotec (NASDAQ:EVO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

OmniAb has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market. Comparatively, Evotec has a beta of 1.96, suggesting that its share price is 96% more volatile than the broader market.

72.1% of OmniAb shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 9.8% of OmniAb shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Evotec has a net margin of -26.20% compared to OmniAb's net margin of -115.12%. OmniAb's return on equity of -16.59% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	-115.12%	-16.59%	-14.82%
Evotec	-26.20%	-24.93%	-11.35%

Evotec has a consensus price target of $3.00, indicating a potential upside of 50.00%. Given Evotec's stronger consensus rating and higher probable upside, analysts clearly believe Evotec is more favorable than OmniAb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Evotec had 1 more articles in the media than OmniAb. MarketBeat recorded 7 mentions for Evotec and 6 mentions for OmniAb. OmniAb's average media sentiment score of 0.29 beat Evotec's score of 0.02 indicating that OmniAb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OmniAb	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Evotec	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

OmniAb has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$38.46M	11.60	-$64.78M	-$0.36	N/A
Evotec	$891.97M	0.80	-$117.12M	N/A	N/A

Summary

Evotec beats OmniAb on 8 of the 14 factors compared between the two stocks.

How does OmniAb compare to Mesa Laboratories?

Mesa Laboratories (NASDAQ:MLAB) and OmniAb (NASDAQ:OABI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Mesa Laboratories has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesa Laboratories	$249.13M	2.31	$6.71M	$1.20	85.54
OmniAb	$38.46M	11.60	-$64.78M	-$0.36	N/A

Mesa Laboratories currently has a consensus price target of $94.00, indicating a potential downside of 8.43%. Given Mesa Laboratories' higher possible upside, equities analysts clearly believe Mesa Laboratories is more favorable than OmniAb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesa Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
OmniAb	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Mesa Laboratories has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, OmniAb has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

90.6% of Mesa Laboratories shares are owned by institutional investors. Comparatively, 72.1% of OmniAb shares are owned by institutional investors. 2.8% of Mesa Laboratories shares are owned by insiders. Comparatively, 9.8% of OmniAb shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Mesa Laboratories has a net margin of 2.69% compared to OmniAb's net margin of -115.12%. Mesa Laboratories' return on equity of 20.96% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesa Laboratories	2.69%	20.96%	8.78%
OmniAb	-115.12%	-16.59%	-14.82%

In the previous week, OmniAb had 3 more articles in the media than Mesa Laboratories. MarketBeat recorded 6 mentions for OmniAb and 3 mentions for Mesa Laboratories. Mesa Laboratories' average media sentiment score of 0.67 beat OmniAb's score of 0.29 indicating that Mesa Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesa Laboratories	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OmniAb	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Mesa Laboratories beats OmniAb on 11 of the 16 factors compared between the two stocks.

How does OmniAb compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and OmniAb (NASDAQ:OABI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 72.1% of OmniAb shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 9.8% of OmniAb shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

OmniAb has a net margin of -115.12% compared to Ginkgo Bioworks' net margin of -259.96%. OmniAb's return on equity of -16.59% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
OmniAb	-115.12%	-16.59%	-14.82%

Ginkgo Bioworks has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market. Comparatively, OmniAb has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

In the previous week, Ginkgo Bioworks had 5 more articles in the media than OmniAb. MarketBeat recorded 11 mentions for Ginkgo Bioworks and 6 mentions for OmniAb. Ginkgo Bioworks' average media sentiment score of 0.37 beat OmniAb's score of 0.29 indicating that Ginkgo Bioworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
OmniAb	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Ginkgo Bioworks presently has a consensus target price of $7.00, suggesting a potential downside of 12.01%. Given Ginkgo Bioworks' higher probable upside, equities analysts clearly believe Ginkgo Bioworks is more favorable than OmniAb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
OmniAb	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

OmniAb has lower revenue, but higher earnings than Ginkgo Bioworks. OmniAb is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.05	-$312.76M	-$5.01	N/A
OmniAb	$38.46M	11.60	-$64.78M	-$0.36	N/A

Summary

Ginkgo Bioworks and OmniAb tied by winning 8 of the 16 factors compared between the two stocks.

How does OmniAb compare to Cytek Biosciences?

OmniAb (NASDAQ:OABI) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

OmniAb has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market.

72.1% of OmniAb shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 9.8% of OmniAb shares are owned by insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

OmniAb has higher earnings, but lower revenue than Cytek Biosciences. OmniAb is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$38.46M	11.60	-$64.78M	-$0.36	N/A
Cytek Biosciences	$201.49M	2.71	-$66.54M	-$0.62	N/A

Cytek Biosciences has a consensus target price of $5.56, suggesting a potential upside of 32.44%. Given Cytek Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cytek Biosciences is more favorable than OmniAb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cytek Biosciences has a net margin of -38.98% compared to OmniAb's net margin of -115.12%. Cytek Biosciences' return on equity of -12.40% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	-115.12%	-16.59%	-14.82%
Cytek Biosciences	-38.98%	-12.40%	-9.17%

In the previous week, Cytek Biosciences had 2 more articles in the media than OmniAb. MarketBeat recorded 8 mentions for Cytek Biosciences and 6 mentions for OmniAb. Cytek Biosciences' average media sentiment score of 0.52 beat OmniAb's score of 0.29 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OmniAb	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cytek Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cytek Biosciences beats OmniAb on 12 of the 16 factors compared between the two stocks.

Get OmniAb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OABI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OABI vs. The Competition

Export

Metric	OmniAb	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$445.93M	$9.43B	$7.00B	$12.99B
Dividend Yield	N/A	1.45%	2.58%	10.20%
P/E Ratio	-8.56	62.85	270.57	25.05
Price / Sales	11.60	104.71	659.56	107.93
Price / Cash	N/A	26.16	28.89	37.44
Price / Book	1.66	5.10	11.20	6.43
Net Income	-$64.78M	$56.66B	$3.45B	$348.10M
7 Day Performance	57.14%	2.97%	3.39%	2.66%
1 Month Performance	34.50%	-0.34%	-0.72%	-0.85%
1 Year Performance	56.35%	22.01%	77.42%	23.96%

OmniAb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OABI OmniAb	0.764 of 5 stars	$3.08 flat	N/A	+56.3%	$445.93M	$38.46M	N/A	7	News Coverage Earnings Report Gap Down High Trading Volume
CYRX CryoPort	3.04 of 5 stars	$15.22 -1.7%	$16.38 +7.6%	+100.0%	$780.73M	$176.18M	11.27	1,186	Earnings Report Analyst Forecast
EVO Evotec	3.7306 of 5 stars	$1.95 +0.5%	$3.00 +53.8%	-49.1%	$690.17M	$891.97M	N/A	4,553	Upcoming Earnings
MLAB Mesa Laboratories	1.4075 of 5 stars	$101.14 -3.2%	$94.00 -7.1%	+59.7%	$584.38M	$249.13M	84.28	680
DNA Ginkgo Bioworks	0.7343 of 5 stars	$9.38 +4.9%	$8.50 -9.3%	-34.9%	$584M	$170.15M	N/A	640	Earnings Report Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OABI) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OmniAb (OABI) Competitors

OABI vs. CYRX, EVO, MLAB, DNA, and CTKB

How does OmniAb compare to CryoPort?

Summary

How does OmniAb compare to Evotec?

Summary

How does OmniAb compare to Mesa Laboratories?

Summary

How does OmniAb compare to Ginkgo Bioworks?

Summary

How does OmniAb compare to Cytek Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OABI vs. The Competition

OmniAb Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OmniAb (OABI) Competitors

OABI vs. CYRX, EVO, MLAB, DNA, and CTKB

How does OmniAb compare to CryoPort?

Which has better earnings and valuation, CYRX or OABI?

Which has more risk & volatility, CYRX or OABI?

Do analysts prefer CYRX or OABI?

Is CYRX or OABI more profitable?

Does the media favor CYRX or OABI?

Do insiders and institutionals have more ownership in CYRX or OABI?

Summary

How does OmniAb compare to Evotec?

Which has more volatility & risk, OABI or EVO?

Do insiders and institutionals believe in OABI or EVO?

Is OABI or EVO more profitable?

Do analysts recommend OABI or EVO?

Does the media refer more to OABI or EVO?

Which has better valuation & earnings, OABI or EVO?

Summary

How does OmniAb compare to Mesa Laboratories?

Which has higher earnings and valuation, MLAB or OABI?

Do analysts rate MLAB or OABI?

Which has more risk & volatility, MLAB or OABI?

Do institutionals & insiders hold more shares of MLAB or OABI?

Is MLAB or OABI more profitable?

Does the media favor MLAB or OABI?

Summary

How does OmniAb compare to Ginkgo Bioworks?

Do institutionals and insiders hold more shares of DNA or OABI?

Is DNA or OABI more profitable?

Which has more volatility and risk, DNA or OABI?

Does the media prefer DNA or OABI?

Do analysts prefer DNA or OABI?

Which has higher earnings & valuation, DNA or OABI?

Summary

How does OmniAb compare to Cytek Biosciences?

Which has more volatility & risk, OABI or CTKB?

Do institutionals & insiders have more ownership in OABI or CTKB?

Which has higher valuation & earnings, OABI or CTKB?

Do analysts prefer OABI or CTKB?

Is OABI or CTKB more profitable?

Does the media refer more to OABI or CTKB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OABI vs. The Competition

OmniAb Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools